ArticleBMC cancer2006
The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis.
Article in BMC cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 79 citations in OpenAlex.
- The function of CD164 in breast cancer and its possibility as a molecular biomarker: bioinformatics analysis and experimental validation.Frontiers in immunology · 2025Article
- Article
- Article
- Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples.Cell systems · 2022Article
- Review
- The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.Cancer metastasis reviews · 2021Review
- Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives.International journal of molecular sciences · 2021Review
- Molecular mechanisms and clinical management of cancer bone metastasis.Bone research · 2020Review
- Adherent Intestinal Cells From Atlantic Salmon Show Phagocytic Ability and Express Macrophage-Specific Genes.Frontiers in cell and developmental biology · 2020Article
- Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis.Frontiers in oncology · 2020Article
- Association of High miR-182 Levels with Low-Risk Prostate Cancer.The American journal of pathology · 2019Article
- CD164 regulates proliferation, progression, and invasion of human glioblastoma cells.Oncotarget · 2019Article
- Human SP-D Acts as an Innate Immune Surveillance Molecule Against Androgen-Responsive and Androgen-Resistant Prostate Cancer Cells.Frontiers in oncology · 2019Article
- CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer.Cancer medicine · 2018Article
- Loss and gain of N-linked glycosylation sequons due to single-nucleotide variation in cancer.Scientific reports · 2018Article
- Alcohol and hepatitis virus-dysregulated lncRNAs as potential biomarkers for hepatocellular carcinoma.Oncotarget · 2018Article
- Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis.Oncology letters · 2017Article
- TheOncotarget · 2017Article
- CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling.Oncotarget · 2017Article
- CD164 regulates proliferation and apoptosis by targeting PTEN in human glioma.Molecular medicine reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundThe chemokine stromal derived factor-1 (SDF-1 or CXCL12) and its receptor CXCR4 have been demonstrated to be crucial for the homing of stem cells and prostate cancers to the marrow. While screening prostate cancers for CXCL12-responsive adhesion molecules, we identified CD164 (MGC-24) as a potential regulator of homing. CD164 is known to function as a receptor that regulates stem cell localization to the bone marrow.
resultsUsing prostate cancer cell lines, it was demonstrated that CXCL12 induced both the expression of CD164 mRNA and protein. Functional studies demonstrated that blocking CD164 on prostate cancer cell lines reduced the ability of these cells to adhere to human bone marrow endothelial cells, and invade into extracellular matrices. Human tissue microarrays stained for CD164 demonstrated a positive correlation with prostate-specific antigen levels, while its expression was negatively correlated with the expression of androgen receptor.
conclusionOur findings suggest that CD164 may participate in the localization of prostate cancer cells to the marrow and is further evidence that tumor metastasis and hematopoietic stem cell trafficking may involve similar processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.